Biologics are large, complex drugs derived from living organisms that have revolutionized medicine. These powerful drugs known as biologics, or biological products, have reshaped treatment options for many serious and life-threatening illnesses from cancer to diabetes and beyond. With biologics emerging as the next frontier in medicine, let’s explore this exciting new world.
What are Biologics?
Biologics, also known as biological products or biopharmaceuticals, are medicines made from biological sources such as genes, tissues, cells or proteins. As opposed to chemically synthesized small molecule drugs, biologics are often large, complex molecules that are manufactured in or extracted from living systems like microorganisms, animal cells, plants or humans. Popular biologics include vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are recombinant proteins produced through genetic engineering techniques where the genes encoding the required proteins are inserted and expressed in living cells such as bacteria or mammalian cells. Once expressed, the proteins are then extracted and purified. The first licensed biologic drug was insulin for diabetes approved in 1982. Since then, numerous other biologics have been developed to treat various diseases.
Mechanisms of Action
Most biologics work by mimicking the action of natural proteins in the body called cytokines or growth factors that play key roles in cell signaling, differentiation and proliferation. For example, erythropoietin is an endogenous protein that stimulates red blood cell production. The recombinant form of erythropoietin known as epoetin alfa is used for the treatment of anemia. Similarly, biologics like interferons and interleukins work by facilitating cell-to-cell communication and modulating immune responses. Gene therapies deliver functional genes to replace non-functional or missing genes to provide cure. Vaccines work by providing a safer form of the disease causing pathogen or its toxic products to stimulate the immune system to produce protective antibodies without causing the disease. The potential of biologics lies in their ability to target disease pathways with high specificity.
Classification of Biologics
Biologics can be broadly classified based on their molecular structure and mechanism of action. Some of the major classes of biologics include:
- Cytokines: Proteins like interferons, interleukins and colony stimulating factors that mediate and regulate immune responses. For example, interferon-alpha is used for hepatitis C and certain cancers.
- Monoclonal antibodies (mAbs): Antibodies engineered in a laboratory to home in on specific targets. Used extensively in oncology, rheumatoid arthritis and other autoimmune diseases.
- Enzymes: Biomacromolecules that catalyze biochemical reactions. Used for treating lysosomal storage disorders and hemophilia.
- Blood components: Whole blood, platelets, clotting factors etc. used for transfusion therapy.
- Gene therapies: Therapies involving genetic material like DNA/RNA to replace faulty genes.
- Vaccines: Weaker versions of pathogens that induce protective immunity against infections.
- Allergenics: Allergen extracts used for immunotherapy of allergic diseases like asthma.
- Recombinant proteins: Therapeutic proteins expressed recombinantly in living cells like insulin, growth hormone etc.
Manufacturing Challenges
Due to their large and complex structure, biologics manufacturing is immensely challenging compared to small molecules. Biologics are produced through living biotechnological or biological processes involving cell cultivation where production of each batch can vary based on cell line and environmental factors. Rigorous quality control testing is required to ensure product consistency, purity, safety and efficacy before approval and commercialization. Production at commercial scales requires large bioreactors and specialized facilities compliant with current Good Manufacturing Practices (cGMP). Developing scalable and robust manufacturing processes is immensely expensive and time-consuming. Along with high production costs, regulatory approvals for biologics also takes longer. These challenges significantly increase the overall costs of biologics compared to small molecule drugs.
Impact on Healthcare
Despite manufacturing challenges, biologics have revolutionized disease management and outcomes in areas like oncology, immunology and hematology. Some key impacts of Biologics on healthcare are:
- Introduction of targeted therapies: Biologics provided the means to target specific molecules and pathways with high accuracy resulting in improved outcomes with lesser side effects than conventional drugs.
- Shift to personalized healthcare: Advances in genetic engineering and protein engineering enabled tailoring of biologics to individual patient profiles and disease subtypes, ushering in an era of personalized medicine.
- Rise of regenerative medicine: Regenerative therapies using stem cells, gene therapies and tissue engineering offer the hope of repairing damaged tissues and potentially curing certain genetic disorders.
- Improved management of formerly fatal conditions: Biologics have transformed the treatment paradigm for many life-threatening illnesses like cancers, hematological disorders which were earlier deemed untreatable or fatal.
- Shift in treatment patterns: Biologics have replaced chemotherapy as a first line treatment option for certain cancers due to proven superiority over conventional drugs. This has led to a fundamental shift in clinical practice guidelines.
- Increase in healthcare expenditures: High costs of manufacturing and developmental uncertainties of biologics have significantly increased overall healthcare expenditures in developing countries adopting biologics.
Future Prospects
With advances in fields of molecular biology, immunology, computer sciences and artificial intelligence, the future of biologics looks very promising. Some exciting upcoming areas are:
- Multi-specific antibodies: Antibodies that can bind multiple targets simultaneously to improve efficacy of cancer and other multifaceted diseases.
- Cell and gene therapies: Curative therapies for genetic disorders through ex-vivo gene editing or in-vivo gene delivery using vectors.
- Vaccines for global health priorities: Vaccines for infectious diseases like HIV/AIDS, tuberculosis and malaria with potential for eradication.
- Personalized biologics: Tailoring biologic doses, combinations and schedules based on disease heterogeneity and individual patient profiles through real-time data.
- Biosimilars: Follow-on versions of innovator biologics that are similar in quality and efficacy offering more affordable treatment options.
- Biomanufacturing advances: Development of closed, automated and continuous manufacturing systems at commercial scales to increase productivity and quality.
With the entry of biosimilars and rising focus on manufacturing and regulatory science, biologics
Get More Information Here: https://www.pressreleasebulletin.com/biologics-biological-therapies-for-disease-management/
The global biopharmaceuticals contract manufacturing market size is expected to reach USD 21.7 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 7.5% during the forecast period.
Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors driving partnerships between large molecule manufacturers and contract manufacturing organizations (CMOs).
Contract manufacturers are engaged in broadening their service portfolio to meet companies’ demand with respect to regulatory standards and new services.Reliance of companies on CMOs for production of biologics and biosimilars is expected to rise over the forecast period as a consequence of changes adopted by CMOs.
This is evident through growing investments in collaborations of companies with CMOs as well as continuous efforts taken up for broadening service portfolios.The growth of CMOs is highly dependent on promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry.
Expansion of fill-and-finish services and increasing robustness of venture capital investments in the life science sector are important opportunities that are anticipated to drive the market.Further key findings from the report suggest:Based on source, mammalian-based biopharmaceutical contract manufacturing captured the largest market share owing to high penetration of mammalian expression systems for biologics developmentBy service, upstream and downstream services accounted for the largest revenue share.
Complexities associated with these steps pronounces demand for established contract manufacturers to ensure manufacturing processes compliant with regulatory standardsBiologics contract manufacturing dominated the market based on product owing to higher demand for biologics production.
